Behandling med celecoxib hos FAP- patienter er blevet fulgt i op til 6 måneder og har ikke vist, at risikoen for gastrointestinal cancer, andre former for cancer eller behovet for kirurgi nedsættes.
Treatment with celecoxib in FAP has been studied for up to 6 months and has not been shown to reduce the risk of gastrointestinal or other form of cancer or the need for surgery.